

Durham Research Online

Deposited in DRO:

14 April 2015

Version of attached file:

Accepted Version

Peer-review status of attached file:

Peer-reviewed

Citation for published item:

Sarkozy, A. and Hicks, D. and Hudson, J. and Laval, S.H. and Barresi, R. and Hilton-Jones, D. and Deschauer, M. and Harris, E. and Rufibach, L. and Hwang, E. and Bashir, R. and Walter, M.C. and Krause, S. and van den Bergh, P. and Illa, I. and Pénisson-Besnier, I. and De Waele, L. and Turnbull, D. and Guglieri, M. and Schrank, B. and Schoser, B. and Seeger, J. and Schreiber, H. and Gläser, D. and Eagle, M. and Bailey, G. and Walters, R. and Longman, C. and Norwood, F. and Winer, J. and Muntoni, F. and Hanna, M. and Roberts, M. and Bindoff, L.A. and Brierley, C. and Cooper, R.G. and Cottrell, D.A. and Davies, N.P. and Gibson, A. and Gorman, G.S. and Hammans, S. and Jackson, A.P. and Khan, A. and Lane, R. and McConville, J. and McEntagart, M. and Al-Memar, A. and Nixon, J. and Panicker, J. and Parton, M. and Petty, R. and Price, C.J. and Rakowicz, W. and Ray, P. and Schapira, A.H. and Swingler, R. and Turner, C. and Wagner, K.R. and Maddison, P. and Shaw, P.J. and Straub, V. and Bushby, K. and Lochmüller, H. (2013) 'ANO5 gene analysis in a large cohort of patients with anoctaminopathy : confirmation of male prevalence and high occurrence of the common exon 5 gene mutation.', *Human mutation.*, 34 (8). pp. 1111-1118.

Further information on publisher's website:

<http://dx.doi.org/10.1002/humu.22342>

Publisher's copyright statement:

This is the accepted version of the following article: Sarkozy, A., Hicks, D., Hudson, J., Laval, S. H., Barresi, R., Hilton-Jones, D., Deschauer, M., Harris, E., Rufibach, L., Hwang, E., Bashir, R., Walter, M. C., Krause, S., van den Bergh, P., Illa, I., Pénisson-Besnier, I., De Waele, L., Turnbull, D., Guglieri, M., Schrank, B., Schoser, B., Seeger, J., Schreiber, H., Gläser, D., Eagle, M., Bailey, G., Walters, R., Longman, C., Norwood, F., Winer, J., Muntoni, F., Hanna, M., Roberts, M., Bindoff, L. A., Brierley, C., Cooper, R. G., Cottrell, D. A., Davies, N. P., Gibson, A., Gorman, G. S., Hammans, S., Jackson, A. P., Khan, A., Lane, R., McConville, J., McEntagart, M., Al-Memar, A., Nixon, J., Panicker, J., Parton, M., Petty, R., Price, C. J., Rakowicz, W., Ray, P., Schapira, A. H., Swingler, R., Turner, C., Wagner, K. R., Maddison, P., Shaw, P. J., Straub, V., Bushby, K. and Lochmüller, H. (2013), ANO5 Gene Analysis in a Large Cohort of Patients with Anoctaminopathy: Confirmation of Male Prevalence and High Occurrence of the Common Exon 5 Gene Mutation. *Human Mutation*, 34 (8): 1111-1118, which has been published in final form at <http://dx.doi.org/10.1002/humu.22342>. This article may be used for non-commercial purposes in accordance With Wiley Terms and Conditions for self-archiving.

Additional information:

Use policy

The full-text may be used and/or reproduced, and given to third parties in any format or medium, without prior permission or charge, for personal research or study, educational, or not-for-profit purposes provided that:

- a full bibliographic reference is made to the original source
- a [link](#) is made to the metadata record in DRO
- the full-text is not changed in any way

The full-text must not be sold in any format or medium without the formal permission of the copyright holders.

Please consult the [full DRO policy](#) for further details.

Durham University Library, Stockton Road, Durham DH1 3LY, United Kingdom

Tel : +44 (0)191 334 3042 | Fax : +44 (0)191 334 2971

<https://dro.dur.ac.uk>



**ANO5 gene analysis in a large cohort of patients with
anoctaminopathy: confirmation of male prevalence and high
occurrence of the common exon 5 gene mutation**

Journal:	<i>Human Mutation</i>
Manuscript ID:	humu-2013-0099.R1
Wiley - Manuscript type:	Research Article
Date Submitted by the Author:	n/a
Complete List of Authors:	<p>Sarkozy, Anna; Institute of Genetic Medicine, Hicks, Debbie; Institute of Genetic Medicine, Hudson, Judith; Institute of Genetic Medicine, Laval, Steven; Institute of Genetic Medicine, Barresi, Rita; NCG Diagnostic & Advisory Service for Rare Neuromuscular Diseases, Muscle Immunoanalysis Unit, Dental Hospital, Hilton-Jones, David; Department of Neurology, West Wing, John Radcliffe Hospital, Deschauer, Marcus; University of Halle-Wittenberg, Neurology Harris, Elizabeth; Institute of Genetic Medicine, Rufibach, Laura; Jain Foundation, Hwang, Esther; Jain Foundation, Bashir, Rumaisa; University of Durham, Biological and Biomedical Sciences Walter, Maggie; Friedrich Baur Institute, Ludwig-Maximilians University, Krause, Sabine; Friedrich Baur Institute, Ludwig-Maximilians University, Van den Bergh, Peter; Université Catholique de Louvain, Brussels, Illa, Isabel; Servei Neurologia, Hospital Sta Creu Sant Pau, Universitat Autònoma de Barcelona; Penisson-Besnier, Isabelle; Département de Neurologie, CHU Dewaele, Liesbeth; Institute of Genetic Medicine, Turnbull, Doug; Newcastle University Centre for Brain Ageing and Vitality, Newcastle University, ; Wellcome Trust Centre for Mitochondrial Research, Institute for Ageing and Health, Newcastle University, Guglieri, Michela; Institute of Genetic Medicine, Schrank, Bertold; Deutsche Klinik für Diagnostik, Schoser, Benedikt; Friedrich Baur Institute, Ludwig-Maximilians University, Seeger, Jurgen; Deutsche Klinik für Diagnostik, Schreiber, Herbert; Neuropoint Patient Academy, (Myology Practice), Glaser, Dieter; Genetikum, Neu-Ulm, Eagle, Michelle; Institute of Genetic Medicine, Bailey, Geraldine; Institute of Genetic Medicine, Walters, Richard; Morriston Hospital, Morriston, Longman, Cheryl; Yorkhill Hospital, Ferguson Smith Centre for Clinical Genetics Norwood, Fiona; Kings College Hospital, Department of Neurology Winer, John; Birmingham Muscle and Nerve Centre, Queen Elizabeth</p>

1	
2	
3	
4	Hospital,
5	Muntoni, Francesco; MRC Centre for Neuromuscular Diseases, UCL Institute
6	of Neurology and National Hospital for Neurology and Neurosurgery, Queen
7	Square, ; Dubowitz Neuromuscular Centre, UCL Institute of Child Health
8	and Great Ormond Street Hospital for Children,
9	Hanna, Michael; MRC Centre for Neuromuscular Diseases, UCL Institute of
10	Neurology and National Hospital for Neurology and Neurosurgery, Queen
11	Square, ; Department of Molecular Neuroscience, UCL Institute of
12	Neurology and National Hospital for Neurology and Neurosurgery, Queen
13	Square,
14	Roberts, Mark; Hope Hospital, Departments of Neurology and
15	Neuropathology
16	Bindoff, Laurence; Department of Clinical Medicine, University of Bergen
17	and Department of Neurology, Haukeland University Hospital,
18	Brierley, Charlotte; Department of Neurology, Addenbrooke's Hospital,
19	Cooper, Robert; University of Manchester Rheumatic Diseases Centre,
20	Salford Royal Foundation Trust,
21	Cottrell, David; Department of Neurology, Frenchay Hospital,
22	Davis, Nick; Birmingham Muscle and Nerve Centre, Queen Elizabeth
23	Hospital,
24	Gibson, Andrew; Sheffield Teaching Hospitals NHS Foundation Trust,
25	Gorman, Gráinne; Wellcome Trust Centre for Mitochondrial Research,
26	Institute for Ageing and Health, Newcastle University,
27	Hammans, Simon; Wessex Neurological Centre, University Hospital of
28	Southampton,
29	Jackson, Andrew; MRC Human Genetics Unit, MRC IGMM, University of
30	Edinburgh,
31	Khan, Aijaz; Royal Hallamshire Hospital, Sheffield Teaching Hospitals,
32	Lane, Russell; Charing Cross Hospital, Imperial College, Department of
33	Clinical Neurosciences
34	McConville, John; Belfast City Hospital,
35	McEntagart, Meriel; St George's University of London, Clinical Genetics
36	Al-Memar, Ali; 34 St George's University Hospital,
37	Nixon, John; Department of Neurology, Royal Preston Hospital,
38	Panicker, Jay; The Walton Centre For Neurology And Neurosurgery,
39	Parton, Matt; MRC Centre for Neuromuscular Diseases, UCL Institute of
40	Neurology and National Hospital for Neurology and Neurosurgery, Queen
41	Square,
42	Petty, Richard; Department of Neurology, Southern General Hospital,
43	Price, Christopher; Department of Neuroscience, Musgrove Park Hospital,
44	Taunton,
45	Rakowicz, Wojtek; Imperial College, Neurology
46	Ray, Partha; The Walton Centre For Neurology And Neurosurgery,
47	Schapira, Anthony; UCL Institute of Neurology and National Hospital for
48	Neurology and Neurosurgery, Queen Square,
49	Swingler, Robert; Department of Neurology, Hospital & Medical School,
50	Turner, Chris; MRC Centre for Neuromuscular Diseases, UCL Institute of
51	Neurology and National Hospital for Neurology and Neurosurgery, Queen
52	Square, ; Department of Molecular Neuroscience, UCL Institute of
53	Neurology and National Hospital for Neurology and Neurosurgery, Queen
54	Square,
55	Wagner, Kathryn; Center for Genetic Muscle Disorders, The Kennedy
56	Krieger Institute and the Departments of Neurology and Neuroscience, The
57	Johns Hopkins School of Medicine,
58	Maddison, Paul; Nottingham University Hospitals,
59	Shaw, Pamela; <none> ,
60	Straub, Volker; Newcastle University, Institute of Human Genetics;
	Bushby, Kate
	Lochmüller, Hanns; 6Institute of Human Genetics, University of Newcastle
	upon Tyne, International Centre for Life,

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Key Words:	ANO5, LGMD2L, gender, common mutation

SCHOLARONE™
Manuscripts

For Peer Review

***ANOS* gene analysis in a large cohort of patients with anoctaminopathy:
confirmation of male prevalence and high occurrence of the common exon 5 gene
mutation**

Anna Sarkozy¹, Debbie Hicks¹, Judith Hudson¹, Steve H Laval¹, Rita Barresi², David Hilton-Jones³, Markus Deschauer⁴, Elizabeth Harris¹, Laura Rufibach⁵, Esther Hwang⁵, Rumaisa Bashir⁶, Maggie C Walter⁷, Sabine Krause⁷, Peter van den Bergh⁸, Isabella Illa⁹, Isabelle Pénisson-Besnier¹⁰, Liesbeth De Waele^{1*}, Doug Turnbull^{11,12}, Michela Guglieri¹, Bertold Schrank¹³, Benedikt Schoser⁷, Jürgen Seeger¹³, Herbert Schreiber¹⁴, Dieter Gläser¹⁵, Michelle Eagle¹, Geraldine Bailey¹, Richard Walters¹⁶, Cheryl Longman¹⁷, Fiona Norwood¹⁸, John Winer¹⁹, Francesco Muntoni²⁰⁻²¹, Michael Hanna^{20,22}, Mark Roberts²³, Laurence A. Bindoff²⁴, Charlotte Brierley²⁵, Robert G Cooper²⁶, David A Cottrell²⁷, Nick P Davis¹⁹, Andrew Gibson²⁸, Gráinne S. Gorman¹², Simon Hammans²⁹, Andrew P. Jackson³⁰, Aijaz Khan³¹, Russell Lane³², John McConville³³, Meriel McEntagart³⁴, Ali Al-Memar³⁴, John Nixon³⁵, Jay Panicker³⁶, Matt Parton²⁰, Richard Petty³⁷, Christopher J Price³⁸, Wojtek Rakowicz³⁹, Partha Ray³⁶, Anthony H Schapira⁴⁰, Robert Swingle⁴¹, Chris Turner^{20,22}, Kathryn Wagner⁴², Paul Maddison⁴³, Pamela J Shaw⁴⁴, Volker Straub¹, Kate Bushby¹ and Hanns Lochmüller¹

1 Institute of Genetic Medicine, International Centre for Life, Newcastle upon Tyne, UK; 2 NCG Diagnostic & Advisory Service for Rare Neuromuscular Diseases, Muscle Immunoanalysis Unit, Dental Hospital, Newcastle upon Tyne, UK; 3 Department of Neurology, West Wing, John Radcliffe Hospital, Oxford, UK; 4 Department of Neurology, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany; 5 Jain Foundation Inc., Bellevue, WA, USA; 6 School of Biological and Biomedical Sciences, University of Durham, Durham, UK; 7 Friedrich Baur Institute, Ludwig-Maximilians University, Munich, Germany; 8 Neuromuscular Reference Center, Saint-Luc University Hospitals, Catholic University of Louvain, Brussels, Belgium; 9 Department of Neurology, Neuromuscular Unit Hospital de la Santa Creu i Sant Pau, U.A.B. and CIBERNED Barcelona, Spain; 10 Département de Neurologie, Centre de référence des Maladies Neuromusculaires, Centre Hospitalier Universitaire d'Angers, Angers, France; 11 Newcastle University Centre for Brain Ageing and Vitality, Newcastle University, Newcastle upon Tyne, UK; 12 Wellcome Trust Centre for Mitochondrial Research, Institute for Ageing and Health, Newcastle University, Newcastle upon Tyne, UK; 13 Deutsche Klinik für Diagnostik, Wiesbaden, Germany; 14 Neuropoint Patient Academy, (Myology Practice), Ulm, Germany; 15 Genetikum, Neu-Ulm, Germany; 16 Morriston Hospital, Morriston, Swansea, UK; 17 Ferguson Smith Centre for Clinical Genetics, Yorkhill Hospital, Glasgow, UK; 18 Department of Neurology, Kings College Hospital, London, UK; 19 Birmingham Muscle and Nerve Centre, Queen Elizabeth Hospital, Birmingham, UK; 20 MRC Centre for Neuromuscular Diseases, UCL Institute of Neurology and National Hospital for Neurology and Neurosurgery, Queen Square, London, UK; 21 Dubowitz Neuromuscular Centre, UCL Institute of Child Health and Great Ormond Street Hospital, London, UK; 22 Department of Molecular Neuroscience, UCL Institute of Neurology and National Hospital for Neurology and Neurosurgery, Queen Square, London, UK; 23 Department of Neurology, Salford Royal NHS Foundation Trust, Salford, United Kingdom; 24 Department of Clinical Medicine, University of Bergen and Department of Neurology, Haukeland University Hospital, Bergen, Norway;

Formatted: English (U.K.)

25 Department of Neurology, Addenbrooke's Hospital, Cambridge, UK; 26 University of Manchester Rheumatic Diseases Centre, Salford Royal Foundation Trust, Salford, UK; 27 Department of Neurology, Frenchay Hospital, Bristol, UK; 28 Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK; 29 Wessex Neurological Centre, University Hospital of Southampton, Southampton, UK; 30 MRC Human Genetics Unit, MRC IGMM, University of Edinburgh, UK; 31 Royal Hallamshire Hospital, Sheffield Teaching Hospitals, Sheffield, UK; 32 Division of Clinical Neurosciences, Imperial College London, UK; 33 Belfast City Hospital, Belfast, UK; 34 St George's University Hospital, London, UK; 35 Department of Neurology, Royal Preston Hospital, Preston, UK; 36 The Walton Centre For Neurology And Neurosurgery, Liverpool, UK; 37 Department of Neurology, Southern General Hospital, Glasgow, UK; 38 Department of Neuroscience, Musgrove Park Hospital, Taunton, Somerset, UK; 39 Department of Neurology, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK; 40 UCL Institute of Neurology and National Hospital for Neurology and Neurosurgery, Queen Square, London, UK; 41 Department of Neurology, Hospital & Medical School, Dundee, UK; 42 Center for Genetic Muscle Disorders, The Kennedy Krieger Institute and the Departments of Neurology and Neuroscience, The Johns Hopkins School of Medicine Baltimore, USA; 43 Nottingham University Hospitals, Nottingham, UK; 44 Academic Units of Neurology, Department of Neuroscience, Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK; * current affiliation: Department of Paediatrics, section Paediatric Neurology, University Hospitals Leuven, Belgium

Corresponding author:

Prof Hanns Lochmüller

Institute of Genetic Medicine

International Centre for Life

Central Parkway

Newcastle upon Tyne

NE1 3BZ

Fax: +44 (0) 191 241 8770

Article Type: Research Article for Human Mutation

Running title: Clinical and molecular analysis of anoctaminopathies

Abstract

Limb girdle muscular dystrophy type 2L or anoctaminopathy is a condition mainly characterized by adult onset proximal lower limb muscular weakness and raised CK values, due to recessive *ANO5* gene mutations. An exon 5 founder mutation (c.191dupA) has been identified in most of the British and German LGMD2L patients so far reported. We aimed to further investigate the prevalence and spectrum of *ANO5* gene mutations and related clinical phenotypes, by screening 205 undiagnosed patients referred to our molecular service with a clinical suspicion of anoctaminopathy. A total of 42 unrelated patients had two *ANO5* mutations (21%), while 14 carried a single change. We identified 34 pathogenic changes, ~~16-135~~ of which are novel. The c.191dupA mutation represents 61% of mutated alleles and appears to be less prevalent in non-Northern European populations. Retrospective clinical analysis corroborates the prevalently proximal lower limb phenotype, the male predominance and absence of major cardiac or respiratory involvement. Identification of cases with isolated hyperCKaemia and very late symptomatic male and female subjects ~~further confirms the broad extension of~~ the phenotypic spectrum of the disease. Anoctaminopathy appears to be one of the most common adult muscular dystrophies in Northern Europe, with a prevalence of about 20-25% in unselected undiagnosed cases.

Key words:

ANO5, LGMD2L, gender, common mutation

Introduction

Limb girdle muscular dystrophy type 2L (LGMD2L) is a condition characterized by proximal weakness affecting primarily the pelvic girdle and leg muscles, with less prominent distal leg weakness and high CK values (Hicks et al, 2011). LGMD2L, together with a more distal variant also known as non-dysferlin Miyoshi muscular dystrophy type 3 (MMD3) as well as some cases of isolated hyperCKaemia and pseudometabolic myopathy, have been shown to be associated with recessive mutations in the *ANO5* gene ([OMIM accession number 608662](#); Bolduc et al, 2010; Hicks et al, 2011; Milone et al, 2012; Deschauer et al, 2012; Schessl et al, 2012; Penttilä et al, 2012; Bouquet et al, 2012; Magri et al, 2012; Pénisson-Besnier et al, 2012; Wahbi et al, 2012; Witting et al, 2012; Little et al, 2013; Neusch et al, 2012). The prevalence of *ANO5* gene related conditions, or so-called anoctaminopathies, is not yet fully established, but preliminary data from Northern England indicate that LGMD2L is the 3rd most common type of LGMD with a minimum prevalence of 0.27/100 000 (Hicks et al, 2011). To date, [35-67 variants](#) ([35 pathogenic; www.lovd.nl/ANO5](#)) mutations have been detected all over the *ANO5* gene, with one a common mutation (c.191dupA) in exon 5, likely the result of a founder effect of Northern European origin (Hicks et al, 2011), and another in exon 20 (c.2272C>T) more frequent in the Finnish population (Penttilä et al, 2012). Early clinical and MRI studies indicated wide clinical heterogeneity and a gender difference in expression, with anoctaminopathies appearing to be less frequent and less severe in females (Sarkozy et al, 2012).

In the present study, we investigated the prevalence and spectrum of *ANO5* gene mutations in the so far largest and clinically most heterogeneous cohort of

Formatted: Font: Times New Roman, Not Bold, Not Highlight

patients with anoctaminopathy, in order to better describe the phenotype, gender predominance and allelic variability of this emerging disease.

Materials and Methods

The study was performed on a total of 205 unrelated individuals of both sexes, referred for *ANO5* gene analysis to the Newcastle upon Tyne Limb-Girdle Referral Centre in view of their phenotypes compatible with anoctaminopathy, ranging from isolated hyperCKaemia, myalgia and raised CK, to MMD3 and LGMD2L. Patients were referred from different clinical centers, but primarily from the UK, Germany, France, Spain, the USA and Belgium. The cohort previously reported by Hicks et al. was not included in this study (Hicks et al, 2011). Clinical details for patients with *ANO5* mutation were collected retrospectively. The clinical suspicion of anoctaminopathy was made following clinical examination, muscle assessment and clinical investigations including CK analysis, EMG, muscle MRI and/or muscle biopsy. Possible alternative diagnoses, such as LGMD2B, LGMD2I and LGMD2A, were excluded as appropriate. DNAs of affected and unaffected relatives were collected and segregation analysis performed where available.

DNA extraction and direct sequencing of the *ANO5* gene (Gene Bank accession number NM_213599.2) was performed as described elsewhere (Hicks et al, 2011). Sequence variants were coded reflecting cDNA numbering with +1 corresponding to the A of the ATG translation initiation codon in the reference sequence, according to guidelines (www.hgvs.org/mutnomen). The initiation codon is codon 1. Novelty of each sequence variant was checked in the *ANO5* locus specific database (www.lovd.nl/ANO5). To investigate whether novel missense, synonymous or intronic variations not located in splice sites could possibly represent pathogenic

Formatted: Font: 12 pt, Not Bold, Font color: Auto, English (U.S.)

Formatted: Font: 12 pt, Not Bold, Font color: Auto, English (U.S.)

Formatted: Font: Italic

Formatted: Font: 12 pt, Not Bold, English (U.S.), Not Highlight

sequence variants, we performed *in silico* analysis using the Alamut mutation analysis software (Interactive Biosoftware, v2.1).

Results

Genetic analysis

ANO5 gene sequence variants were identified in 90/205 unrelated individuals (46%) and 5 affected relatives (Table 1, [Suppl. Table 1](#)). Fifty-one patients were found to carry 2 or more *ANO5* variants in homozygosity or compound heterozygosity, while further 39 patients showed one single *ANO5* change (Tables 1 and 2). A total of 42 *ANO5* gene variants were identified, [32-27](#) of which novel (Tables 1 and 2). Twenty variants were missense (47%), 4 frameshift (9%), 6 splice site (14%), 2 stop (5%), 1 synonymous (2%) and 10 intronic (24%) (Table 2). The pathogenicity of [16-135](#) novel variants is supported by their predicted effect on protein product, by their recurrence in multiple unrelated patients, by segregation in affected family members, absence in SNPs databases and *in silico* analysis. Four missense changes, two of which were previously reported in literature as pathogenic (c.155A>G and c.2387C>T), were considered benign variants based on *in silico* analysis and/or their frequency in control population (Table 2) (Wahbi et al, 2012). It was not possible to further comment on the pathogenicity of a missense (c.968C>G) and a synonymous change (c.2256G>A) as well as 10 intronic variants in absence of segregation studies or further cDNA investigations.

~~Forty two~~Forty-two unrelated [patients \(N.1-N.42\)](#) carried 2 likely pathogenic *ANO5* gene changes, [24-19](#) in homozygosity and [20-283](#) in compound heterozygosity (Table 1). [Patients N.21B, N.22B, N.28B, N.40B-C carried the pathogenic variants found in their affected relative \(i.e. N.21A, N.22A, N.28A and N.40A\).](#) In 14 patients [\(N.43-N.56\)](#) only one single pathogenic variant was identified. cDNA analysis or

genomic dosage analysis was not performed to rule out a possible 2nd deep intronic change or deletion/duplication of the part/entire *ANO5* gene. Seven novel pathogenic variants were recurrent (Tables 1 and 2). The common c.191dupA exon 5 mutation was found in homozygosity in 16 patients, in compound heterozygosity with another identified mutation in 19, and in heterozygosity without a 2nd detectable mutation in further 5 individuals. Geographic origin of patients, indicated in Table 1, confirms that the common variant is present also in populations other than the British and German populations. Additionally, two already reported (c.692G>T, c.1927dupA) and 2 novel (c.1898+1G>A, c.2417A>G) mutations were also identified in multiple patients, and further 3 novel changes were found in homozygosity in 3 individuals (Tables 1 and 2). Parental DNA screening or *ANO5* genomic dosage analysis was not performed yet for the homozygous patients, and hemizyosity of parts or the entire *ANO5* locus cannot be ruled out.

Phenotypic analysis

Among patients with 2 likely pathogenic changes (total 47 patients, including 42 unrelated subjects and 5 affected relatives), 39 were male (83%) and 8 were female (17%). Clinical information was available for 41/44 patients and relatives with 2 pathogenic changes 44 patients (34 males, and 7 females) (table 3). Thirty-four patients (83%) were male and 7 were female (17%). Age at onset ranged between teens and late 70s, with an average age at onset of 35 years. At time of genetic diagnosis, 3/7 females and 3/374 males were completely asymptomatic or very mildly symptomatic. Average CK values were 4000 IU/l, ranging from around 200 IU/l up to about 30.000 IU/L. Detailed information about last muscle assessment At time of last assessment was available for 38/47 individuals, a A predominantly proximal involvement was observed in 22/38 (57%) patients, while 4/38 (10%) and 3/38 (8%)

1
2
3
4
5
6 patients showed a more distal or proximal plus distal involvement, respectively. No or
7
8 very mild clinical symptoms (myalgia and/or raised CK) were reported in 9 patients
9
10 with 2 *ANO5* mutations (25%).

11
12 Symptoms at onset and overall clinical presentation in males were similar to
13
14 what has been previously described for patients with *ANO5* gene mutations (Table 3;
15
16 Hicks et al, 2011). Although age at onset was similar on average (34 years), in this
17
18 cohort we observed a wider range, with patients showing first symptoms in their teens
19
20 to patients only symptomatic in late adulthood, with one patient (Pt. N.38) showing
21
22 first symptoms of proximal lower limb weakness and wasting at the age of 77 years
23
24 only. Moreover, the phenotype was extremely mild in 3 individuals, only showing
25
26 raised CK values (Pt. N.15 and N.36) or some mild proximal leg weakness after a
27
28 disease course of 32 years (Pt. N.40B). Patient N.21B was diagnosed as part of family
29
30 screening and showed no symptoms of the disease. CK values were not available at
31
32 the time of study.

33
34 Five female individuals (N.03, N.21A, N.27, N.28B, 40C), with an age at last
35
36 assessment ranging from 14 to 68 years, showed raised CK values only or asymmetric
37
38 calf atrophy, while female patients N.02 and N.14, aged 68 and 42 years respectively,
39
40 showed a more pronounced LGMD type weakness. Female patient N.08 (not included
41
42 in table 3 in view of lack of -detailed clinical information) was diagnosed as part of a
43
44 family screening of a previously reported LGMD2L patient. At the age of 44 years
45
46 she does not report any clinical symptoms, but no further clinical information was
47
48 available at time of the study.

49
50 A total of 7 unrelated patients were confirmed with anoctaminopathy, but did
51
52 not carry the common c.191dupA mutation on either allele. Age at onset was 44 years
53
54 on average. Four patients showed a milder phenotype, with a very late onset (77
55
56
57
58
59
60

years), normal power or only mild proximal weakness at last assessment. Muscle wasting was present in half of them, while upper limb function was normal in all.

Clinical information ~~were was~~ available for 11/14 unrelated patients with one single pathogenic variant (data not shown). Five individuals showed a phenotype compatible with a diagnosis of LGMD2L, while 3 subjects only showed raised CK values with or without calf hypertrophy. In one individual (Pt N.50) this variant was also found in further two family members also affected by isolated hyperCKaemia.

~~Clinical analysis of the 7 patients with putatively non pathogenic exonic mutations (Pt. N57-63) showed phenotypes not typical for anoctaminopathy, with lower CK values, more severe upper limb involvement or early age at onset (data not shown). Phenotypic analysis of patients with intronic changes only (Pt. N 64-90) was not performed.~~

Discussion

In this study we report on the clinical analysis and molecular screening of the *ANO5* gene in the largest cohort of anoctaminopathy patients identified so far. Our results confirm the high frequency of the common c.191dupA mutation which represents 51/84 (61%) of mutated alleles in the cohort of patients with two mutations (Tables 1 and 2). Occurrence of this Northern European founder mutation in patients of different geographic origin indicates that it has likely spread worldwide, although at lower frequencies compared to the British and German populations. This is corroborated by the observation that the mutation has not been observed in homozygosity in other populations, with the exception of two unrelated French patients (Wahbi et al, 2012). However, our result could have been biased by the predominance of British and German patients in our cohort.

We identified [34-27](#) novel variants in the *ANO5* gene, [16-135](#) of which are likely pathogenic (Tables 1 and 2). Mutations are spread across the gene, indicating the absence of additional mutation hot spots, although some mutations appear to be recurrent (Tables 1 and 2). The frequency of the second most common variant (c.692G>T) suggests that it could represent an additional common change in our population (Table 1). Interestingly, the common Finnish mutation appears to be rare in our cohort, with a single occurrence in a German patient in compound heterozygosity with the c.191dupA mutation (Pt N.35). Mutations leading to loss of protein function (frameshift, splice and stop mutations) were the most common changes in the “2-mutation” group of patients (66/84 alleles, 79%) although the relative frequency of missense changes (18/84 alleles, 21%) could imply further pathogenetic mechanisms.

We have identified several exonic changes that appear to be benign variants or to have uncertain pathogenicity. Among these, the non pathogenic variant c.155A>G (p.Asn52Ser) in exon 4 (dbSNP rs143777403), found with allelic frequency of 0.0001-0.001 in North American and African American control populations, was identified in 5 patients from our cohort. The c.2387C>T (p.Ser796Leu) in exon 22, also a benign variant by *in silico* analysis, was found in another individual. Interestingly, these two missense variants were described as pathogenic by Wahbi and coauthors (2012) in 3 unrelated subjects, one of which was compound heterozygous for this and the c.155A>G variant. These findings point towards caution when novel missense changes are found (especially if in compound heterozygosity), and no further data corroborating the pathogenicity of the change is available. We identified 3 patients who were homozygous for a novel variant and 14 patients with 1 heterozygous change only. One of the limitations of this study is the lack of cDNA

1
2
3
4
5
6 studies to exclude 2nd deep intronic changes or gene dosage analysis, but
7
8 deletion/duplication analysis is currently in progress in some of these individuals.
9

10 We have previously described the clinical phenotype of anoctaminopathies as
11 an adult onset disease, characterized by slowly progressive muscle weakness mainly
12 affecting the pelvic girdle and the lower limbs (Hicks et al, 2011). Clinical analysis of
13 the present cohort of patients extends our initial findings to a large group of patients
14 not restricted to the common founder mutation (Table 3). Being our center the only
15 currently offering *ANO5* screening in the UK, the prevalence of proximal disease is
16 unlikely to be caused by the referral bias previously suggested (Hicks et al, 2011). No
17 major significant cardiac or respiratory disease was observed in this cohort,
18 suggesting that these are not major features of the condition. We provide further
19 evidence for male predominance in anoctaminopathies, females being overall less
20 frequently and less severely affected than males (Hicks et al, 2011, Penttilä et al,
21 2012). Phenotypic analysis of the here reported affected females reveals a milder
22 clinical picture, with 5 patients showing only raised CK values or calf hypertrophy.
23 The oldest female individual, homozygous for the common exon 5 mutation, showed
24 a late disease onset (64 years), and at the age of 68 years she was still ambulant and
25 she was able to stand on tiptoes and heels with minor difficulties. These findings
26 suggest that gender differences could be in part due to the milder phenotype of
27 affected females that is therefore less likely to be ascertained. In fact, two
28 asymptomatic females were identified after a molecular diagnosis was reached in their
29 brothers. Recruitment bias could also be in part be responsible for gender difference,
30 as patients seen in specialized centers usually show a more severe phenotype, and
31 therefore females with milder phenotypes might not come as frequently to our
32 attention. In this study, we also identified 4 male subjects showing a very mild
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6 phenotype, ranging from isolated hyperCKaemia to mild proximal leg weakness with
7
8 onset in late adulthood (Table 3). In particular, one subject only showed symptoms in
9
10 his late 70s, confirming that indeed age at onset and severity of anoctaminopathies
11
12 can be extremely variable also in males (Hicks et al, 2010; Schessler et al, 2012;
13
14 Penttilä et al, 2012).

15
16 No genotype-phenotype correlations were noted in anoctaminopathy so far.
17
18 Nevertheless, a clinical comparison between patients carrying the common exon 5
19
20 mutation and those carrying different changes revealed some interesting findings
21
22 (Table 1 and 3). Pattern of muscle involvement and female/male ratio appear similar,
23
24 although the phenotype is somehow milder, with onset at later age in patients carrying
25
26 mutations other than the c.191dupA. Unfortunately the relatively low number of
27
28 patients with different *ANO5* changes does not allow any statistically significant
29
30 conclusions. Conversely, phenotypic analysis of heterozygous patients did not
31
32 evidence major differences compared to patients with two mutations, although 3
33
34 heterozygous patients presented raised CK values and mild calf hypertrophy only.
35
36 While we cannot exclude a second non-yet identified change in these subjects, family
37
38 analysis of one individual (Pt. N.50) showed that raised CK values segregated with
39
40 the heterozygous mutation in 2 other family members (data not shown). An
41
42 association between isolated hyperCKaemia and *ANO5* heterozygous carrier status
43
44 was suggested by Milone and coworkers, who identified an otherwise asymptomatic
45
46 carrier of the c.191dupA mutation (Milone et al, 2011). Likewise, isolated
47
48 hyperCKaemia or very mild phenotypes were also found in a few male and female
49
50 patients carrying two pathogenic *ANO5* mutations (Hicks et al, 2011; Schessler et al,
51
52 2012; Penttilä et al, 2012, Wahbi et al, 2012). Systematic analysis of *ANO5* gene in
53
54
55
56
57
58
59
60

wider cohort of subjects with isolated hyperCKaemia, as well as CK measurements in otherwise healthy heterozygous family members could help to clarify these findings.

Our results show that *ANO5* gene mutations are responsible for about ¼ of cases of undiagnosed muscular dystrophy with adult onset and raised CK, screened at our service over the last two years (present series and Hicks et al, 2011). This value is similar to what reported in the Finnish population (Penttilä et al, 2012) and indicates anoctaminopathy as one of the most common form of LGMD in our population, possible reflection of the founder effects observed in Northern Europe (Hicks et al, 2011). Indeed, observed incidences in the UK and Finland are higher than in Italy (Magri et al, 2012) where only about 2% of undiagnosed LGMD patients were shown to carry *ANO5* mutations. Based on its relative frequency, screening of the *ANO5* gene now represents an early step in the diagnostic work-up of these patients.

However, in view of the increasing genetic heterogeneity and prevalence of families without the common mutation (14%), analysis should not be limited to founder mutations only (Penttilä et al, 2012). More systematic studies on isolated hyperCKaemia patients will also help in giving better prevalence data for anoctaminopathies in general.

In conclusion, we confirmed that *ANO5* gene mutations are responsible for about ¼ of cases of undiagnosed muscular dystrophy in our population, being the exon 5 change the most prevalent. We expanded the allelic heterogeneity of the disease and recognized a broader clinical spectrum of the disease, ranging from isolated hyperCKaemia to full blown LGMD2L, with clear male predominance both in terms of overall prevalence and severity of the disease.

Acknowledgments

1
2
3
4
5
6 The authors would like to thank the patients who took part in this study.
7

8 Diagnostic facilities at the Newcastle Muscle Centre are supported by the National
9
10 Specialised Commissioning Team (NSCT) for rare neuromuscular disorders. The
11
12 Institute of Genetic Medicine in Newcastle is part of the MRC Centre for
13
14 Neuromuscular Diseases and the TREAT-NMD Alliance (www.treat-nmd.eu).
15

16 There are no conflicts of interest to declare.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

References

- Bolduc V, Marlow G, Boycott KM, Saleki K, Inoue H, Kroon J, Itakura M, Robitaille Y, Parent L, Baas F, Mizuta K, Kamata N, et al. 2010. Recessive mutations in the putative calcium-activated chloride channel Anoctamin 5 cause proximal LGMD2L and distal MMD3 muscular dystrophies. *Am J Hum Genet* 86:213-21.
- Bouquet F, Cossée M, Béhin A, Deburgrave N, Romero N, Leturcq F, Eymard B. 2012. Miyoshi-like distal myopathy with mutations in anoctamin 5 gene. *Rev Neurol (Paris)* 168:135-41.
- Deschauer M, Joshi PR, Gläser D, Hanisch F, Stoltenburg G, Zierz S. 2011. Muscular dystrophy due to mutations in anoctamin 5 : Clinical and molecular genetic findings. *Nervenarzt* 82:1596-603.
- Hicks D, Sarkozy A, Muelas N, Koehler K, Huebner A, Hudson G, Chinnery PF, Barresi R, Eagle M, Polvikoski T, Bailey G, Miller J, et al. 2011. A founder mutation in Anoctamin 5 is a major cause of limb-girdle muscular dystrophy. *Brain* 134:171-82.
- Little AA, McKeever PE, Gruis KL. 2013. Novel mutations in the anoctamin 5 gene (ANO5) associated with limb-girdle muscular dystrophy 2L. *Muscle Nerve* 47:287-91 [Epub ahead of print]
- Magri F, Bo RD, D'Angelo MG, Sciacco M, Gandossini S, Govoni A, Napoli L, Ciscato P, Fortunato F, Brighina E, Bonato S, Bordoni A, et al. 2012. Frequency and characterisation of anoctamin 5 mutations in a cohort of Italian limb-girdle muscular dystrophy patients. *Neuromuscul Disord* 22:934-43
- Milone M, Liewluck T, Winder TL, Pianosi PT. 2012. Amyloidosis and exercise intolerance in ANO5 muscular dystrophy. *Neuromuscul Disord* 22:13-5

- 1
2
3
4
5
6 Penttilä S, Palmio J, Suominen T, Raheem O, Evilä A, Muelas Gomez N, Tasca G,
7
8 Waddell LB, Clarke NF, Barboi A, Hackman P, Udd B. 2012. Eight new
9
10 mutations and the expanding phenotype variability in muscular dystrophy caused
11
12 by ANO5. *Neurology* 78:897-903
13
- 14 Pénisson-Besnier I, Saint-André JP, Hicks D, Sarkozy A, Croué A, Hudson J,
15
16 Lochmüller H, Dubas F. 2012. Myopathy caused by anoctamin 5 mutations and
17
18 necrotizing vasculitis. *J Neurol* 259:1988-90.
19
- 20 Sarkozy A, Deschauer M, Carlier RY, Schrank B, Seeger J, Walter MC, Schoser B,
21
22 Reilich P, Leturq F, Radunovic A, Behin A, Laforet P, et al. 2012. Muscle MRI
23
24 findings in limb girdle muscular dystrophy type 2L. *Neuromuscul Disord* 22
25
26 Suppl 2:S122-9.
27
- 28 Schessl J, Kress W, Schoser B. Novel ANO5 mutations causing hyper-CK-emia, limb
29
30 girdle muscular weakness and Miyoshi type of muscular dystrophy. 2012. *Muscle*
31
32 *Nerve* 45:740-2.
33
- 34 Wahbi K, Béhin A, Bécane HM, Leturcq F, Cossée M, Laforêt P, Stojkovic T, Carlier
35
36 P, Toussaint M, Gaxotte V, Cluzel P, Eymard B et al. 2012. Dilated
37
38 cardiomyopathy in patients with mutations in anoctamin 5. *Int J Cardiol* [Epub
39
40 ahead of print]
41
- 42 Witting N, Duno M, Born AP, Vissing J. 2012. LGMD2L with bone affection:
43
44 overlapping phenotype of dominant and recessive ANO5-induced disease.
45
46 *Muscle Nerve* 46:829-30.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Table N1. Patients with ANO5 gene mutations

Patient	allele 1	allele 2	Geographic origin
Patients with 2 pathogenic variants			
N.01-N.16	c.191dupA	c.191dupA*	Great Britain (12); Germany (4)
N.17-N.22B	c.191dupA	c.692G>T	Great Britain (7)
N.23	c.191dupA	c.762+1G>A	Great Britain
N.24	c.191dupA	c.1391C>A	USA
N.25	c.191dupA	c.1407+5G>T	Belgium
N.26-N.27	c.191dupA	c.1627dupA	Spain, n.a.
N.28A-N.28B	c.191dupA	c.1643C>T	Germany (2)
N.29	c.191dupA	c.1733T>C	Great Britain
N.30-N.32	c.191dupA	c.1898+1G>A	Great Britain, Poland and USA
N.33	c.191dupA	c.2395C>T	Great Britain
N.34	c.191dupA	c.2417A>G	USA
N.35	c.191dupA	c.2272C>T	Germany
N.36	c.401A>G	c.1898+1G>A	Great Britain
N.37	c.1639C>T	c.1639C>T	n.a.
N.38	c.2030-1G>T	c.2030-1G>T	Great Britain
N.39	c.2236-13_2236-4delinsATTCTTCTGGC	c.2236-13_2236-4delinsATTCTTCTGGC	Great Britain
N.40A-N.40C	c.242A>G	c.1097A>G	Germany (3)
N.41	c.400C>T	c.2235+1G>A	France
N.42	c.989dupTex10	c.2018A>G	Great Britain
Patients with 1 pathogenic variant			
N.43-N.44	c.191dupA	c.155A>G	Great Britain; n.a.
N.45-N.47	c.191dupA		Germany (2); Great Britain
N.48-N.50	c.692G>T		Great Britain (3)
N.51	c.762+1G>A	c.155A>G	USA
N.52	c.1925G>T	c.1181-21T>A	Great Britain
N.53	c.1640G>A	-	Great Britain

- Formatted: Highlight
- Formatted: Highlight
- Formatted ... [1]
- Formatted ... [2]
- Formatted ... [3]
- Formatted ... [4]
- Formatted ... [5]
- Formatted ... [6]
- Formatted ... [7]
- Formatted ... [8]
- Formatted ... [9]
- Formatted ... [10]
- Formatted ... [11]
- Formatted ... [12]
- Formatted ... [13]
- Formatted ... [14]
- Formatted ... [15]
- Formatted ... [16]
- Formatted ... [17]
- Formatted ... [18]
- Formatted ... [19]
- Formatted ... [20]
- Formatted ... [21]
- Formatted ... [22]
- Formatted ... [23]
- Formatted ... [24]

1

N.54	c.2417A>G	-	Great Britain
N.55	c.2521C>G	-	Great Britain
N.56	c.2593A>C	-	Pakistan
Patients with exonic and intronic changes with uncertain pathogenicity			
N.57-N.58	e.155A>G	-	Great Britain (2)
N.59	e.746C>G	-	Great Britain
N.60	e.968C>G	-	Pakistan
N.61	e.2256G>A	-	Great Britain
N.62	e.2387C>T	-	Great Britain
N.63	e.2698A>C	-	Germany
N.64-67	e.364-8dupT	e.364-8dupT	Africa and Great Britain
N.68	e.1119+35G>A	e.1181-48T>A	Germany
N.69	e.139-59dupT	-	n.a.
N.70-78	e.364-8dupT	-	Africa and Great Britain

Note: *ANO5* gene. Gene Bank accession number NM_213599.2. Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the ATG translation initiation codon in the reference sequence, according to journal guidelines (www.hgvs.org/mutnomen). The initiation codon is codon 1.
 Legend: *patient N.05 and N.13 also with variant c.364-67T>C with uncertain pathogenicity.

Formatted Table

Formatted: Indent: Left: 0"

0 PM
1
2
3
0 PM
5
6
0 PM
8
9
0 PM
11
12
0 PM
14
15
0 PM
17
18
0 PM
20
21
0 PM
23
24
0 PM
26
27
0 PM
29
30
0 PM
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

0 PM

1
0 PM

3

4
0 PM

6

7
0 PM

9

10
0 PM

12

13
0 PM

14

15

16
0 PM

17

18

19
0 PM

20

21

22
0 PM

26

27
0 PM

29

30
0 PM

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

For Peer Review

0 PM

1

2

0 PM

4

5

0 PM

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

For Peer Review

Table 2: List of detected *ANOS* gene changes

Nucleotidic change	Amino acidic change	Exon Intron	Protein domain	Zygoty	Reported	Interpretation?
c.139-59dupT		IVS3	CTD	1 HzPt	novel	benign in silico
c.155A>G	p.Asn52Ser	4	CTD	3 CHzPt + 2 HzPt	reported	benign in silico
c.191dupA		5	CTD	16 HomoZpt+ 19 CHzPt + 5 HzPt	reported	frameshift mutation
c.242A>G	p.Asp81Gly	5	CTD	1 CHzPt	reported	pathogenic missense change
c.364-8delT		IVS7	CTD	5 HomoZpt+ 8 HzPt	novel reported	unconfirmed pathogenicity
c.364-67T>C		IVS7	CTD	2 HzPt	novel	unconfirmed pathogenicity
c.400C>T	p.His134Tyr	7	CTD	1 CHzPt	novel	pathogenic in silico
c.401A>G	p.His134Arg	7	CTD	1 CHzPt	novel	pathogenic in silico
c.692G>T	p.Gly231Val	8	CTD	5 CHzPt+ 3 HzPt	reported	pathogenic missense change
c.746C>G	Ala249Gly	8	CTD	1 HzPt	novel	benign in silico
c.762+1G>A		IVS8	CTD	1 CHzPt+1 HzPt	novel	putative splice mutation
c.878+78delT		IVS9	CTD	1 HzPt	novel	benign in silico
c.879-41A>T		IVS9	CTD	1 HzPt	novel	unconfirmed pathogenicity
c.968C>G	p.Ala323Gly	10	CTD	1 HzPt	novel	unconfirmed pathogenicity
c.989dupT		10	CTD	1 CHzPt	novel	frameshift mutation
c.1097A>G	p.Asn366Ser	11	ETD 1	1CHzPt	novel reported	pathogenic in silico
c.1119+35G>A		IVS11	ETD 1	1 CHzPt	novel	unconfirmed pathogenicity
c.1120-24A>T		IVS12	ETD1	2 HzPt	novel	unconfirmed pathogenicity
c.1181-21T>A		IVS13	TMD2	1 HzPt	novel	unconfirmed pathogenicity
c.1181-48T>A		IVS13	TMD2	1 CHzPt +8 HzPt	novel	unconfirmed pathogenicity
c.1391C>A	Ala464Asp	14	TMD3	1 CHzPt	novel	pathogenic in silico
c.1407+5G>T		IVS14	TMD3	1 CHzPt	reported	putative splice mutation
c.1627dupA		15	CTD3	2 CHzPt	reported	frameshift mutation
c.1639C>T	p.Arg547STOP	16	CTD3	1 HomoZpt	novel	stop mutation
c.1640G>A	p.Arg547Gln	16	CTD3	1 HzPt	novel	pathogenic in silico
c.1643C>T	pThr548Ile	16	CTD3	1 CHzPt	reported	pathogenic in silico
c.1733T>C	Phe578Ser	16	CTD3	1 CHzPt	reported	pathogenic missense change

c.1898+1G>A		IVS17	ETD3	4 CHzPt	reported	putative splice mutation
c.1925G>T	Arg642Leu	18	ETD3	1 HzPt	novel	pathogenic in silico
c.2018A>G	Tyr673Cys	18	ETD3	1 CHzPt	reported	pathogenic missense change
c.2030-1G>T		IVS18		1 HomoZpt	novel	putative splice mutation
c.2235+1G>A		IVS19	TMD7	1 CHzPt	novel	putative splice mutation
c.2236-13_2236-4delinsATTCTTCTGGC		20	TMD7	1 HomoZpt	novel	frameshift mutation
c.2256G>A		20	TMD7	1 HzPt	novel	unconfirmed pathogenicity
c.2272C>T	Arg758Cys	20	TMD7	1 CHzPt	reported	pathogenic missense change
c.2387C>T	p.Ser796Leu	20	TMD7	1 HzPt	reported	benign in silico
c.2395C>T	p.Arg799STOP	20		1 CHzPt	novel	stop mutation
c.2417A>G	p.Tyr806Cys	21	ETD4	1 CHzPt+ 1 HzPt	novel	pathogenic in silico
c.2521-13A>G		IVS21	TMD8	1 HzPt	novel reported	unconfirmed pathogenicity
c.2521C>G	p.His841Asp	22	TMD8	1 HzPt	novel	pathogenic in silico
c.2593G>T	p.Ile865Leu	22	TMD8	1 HzPt	novel	pathogenic in silico
c.2698A>C	p.Met900Leu	22	CTD5	1 HzPt	novel	benign in silico

Note: *ANO5* gene, Gene Bank accession number NM_213599.2. Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the ATG translation initiation codon in the reference sequence, according to journal guidelines (www.hgvs.org/mutnomen). The initiation codon is codon 1.

Legend: CTD: cytoplasmic topological domain; ETD: extracellular topological domain; TMD: transmembrane domain; CHzPt: compound heterozygous patient, HzPt: heterozygous patient; HomoZpt: homozygous patient; IVS: intron

Table 3: Phenotypic analysis of patients with 2 pathogenic *ANO5* variants

Patient	Age (years)	Sex	Onset		CK (IU/L)	Pattern of Muscle involvement at last assessment									other features	
			Age	Symptoms		ambulant	UL prox	LL Prox	LL Distal	Walk on toes	Walk on heels	Muscle atrophy	scapular winging	AS		
N.01	50	m	38	thigh weakness	241-2603	yes	-	+++	-	diff.	diff.	thighs	-	+	-	
N.02	68	f	64	proximal LL weakness, thigh wasting	n.a.	yes	+/-	+++	-	diff	diff	thighs and calves (AS)	-	+		
N.03	20	f	-	-	3300-8800	yes	-	-	-	able	able	-	-	-	-	
N.04	63	m	50s	walking difficulties	2122	yes	+/-	+++	+	n.a.	n.a.	-	-	-	calf hypertrophy, KH	
N.05	44	m	20s	Thigh and calf wasting (AS)	4060	yes	-	+++	+/-	able	able	calves, thighs (AS)	-	+	Calf hypertrophy (as child), TA contractures, ptosis	
N.06	35	m	20s	calf swelling, back pain, leg weakness	1642-3080	yes	+/-	++	++ (AS)	unable	unable	-	-	+	muscle twitching, TA contractures	
N.07	56	m	40s	LL weakness and wasting	1517	yes	++	+++	+	unable	unable	n.a.	-			
N.09	40	m	20s	reduces sport fitness and muscle wasting	4000	yes	+/-	++	-	able	able	biceps/pectoral. quads (AS)	-	+		
N.10	64	m	46	Raised CK and myalgia	2200-3300	yes	+/-	+	-	able	able	quads	-	-	Sleep apnoea, CTS	
N.11	43	m	20s	n.a.	5400	yes	no	-	+	diff	diff	calves (AS)	-	+	thigh hypertrophy	
N.12	16	m	16	myalgia, raised CK	2000-30,000	yes	+/-	-	-	able	able	-	-	-	neck flexion weakness	
N.13	70	m	38	Difficulty running and calf asymmetry	1800	yes	+/-	+	(AS)	+	unable	unable	biceps and calves (AS)	-	+	Calf hypertrophy (AS)
N.14	42	f	30s	prox LL weakness	2500-3000	yes	-	+	-			vasti	+/-	n.a.	calf hypertrophy, CTS	
N.15	67	m	50s	raised CK and myalgia	2100	yes	-	-	-	able	able	-	-	n.a.	calf hypertrophy	
N.16	44	m	40	Myalgia	1500-2500	yes	+/-	-	-	able	able	-	+	-		
N.17	47	m	20s	myalgia	1600-6000	yes	-	+++	-	able	unable	thighs, hamstrings especially, calf (AS)	-	+	thigh hypertrophy, CTS	
N.18	65	m	30s	walking difficulties	3661	no 60yrs	-	++++	-	unable	unable	quads	-	-	calf hypertrophy	

N.19	40	m	34	LL weakness	5000	yes	-	+++	+/-	able	able	hamstrings, buttocks, calves	-	-	
N.20	65	m	40s	walking difficulties	2000	yes	-	+	-	n.a.	n.a.	n.a.	-	n.a.	
N.21A	14	f	-	-	1200	Yes	-	-	-	able	able	-	-	-	-
N.21B	17	m	-	-	n.a.	-	-	-	-	able	able	-	-	-	-
N.22A	72	m	50s	walking difficulties	900	yes	+	+++	n.a.	diff	diff	+	+	+	
N.22B	74	m	40s	UL weakness	900	yes	+	+	n.a.	diff	diff	medial gastrocnemius (AS)	+	+	calf, paraspinal muscle hypertrophy
N.23	41	m	38	LL weakness and wasting	209-6301	yes	+/-	+++	-	unable	diff	thighs and calves (AS)	+	+	KH (AS)
N.24	55	m	28	weakness in gastrocnemius muscle	2500-4500	yes	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	
N.25	42	m	23	Wasting and weakness left calf	5300-12500	yes	-	-	++	unable	able	calves	-	+	
N.27	41	f	34	hyperCKaemia	2503	yes	-	-	-	able	able	gastrocnemius medialis (AS)	-	+	
N.28A	56	m	40	asymmetric thigh weakness	1500-6100	yes	+/-	++	-	diff	diff.	Thighs (AS)	-	+	
N.28B	53	f	-	-	2280	yes	-	-	-	able	able	-	-	-	
N.29	64	m	30s	difficulties with climbing stairs	829	yes	+/-	+++	+++	unable	unable		-	+	calf hypertrophy (AS), IHD Anaemia, FVC 70%
N.30	61	m	30	weakness in LL muscles	5956	yes	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	
N.31	28	m	20	difficulties running	7868	yes	-	+++	-	able	able	UL, hamstrings, buttocks, quads	-	+	sensory axonal polyneuropathy
N.32	52	m	20s	hyperCKaemia and calf wasting	>3000	yes	+/-	+++	-	unable	able	vastus medialis, calf (AS)	+/-	+	TA contractures
N.33	32	m	20s	LGMD type weakness	n.a.	restricted	-	+/-	+	n.a.	n.a.	biceps, medial quads, calf (AS)	n.a.	+	
N.34	32	m	22	calf wasting, unable to stand on toes	10,000	yes	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	
N.35	29	m	23	Calf muscles stiffness when walking	1700-2900	yes	-	-	+/-	diff	unable (AS)	calves (AS)	-	+	
N.36	54	m	32	proximal LL weakness	4029	yes	-	+/-	-	able	able	-	-	-	
N.38	77	m	77	proximal LL weakness and raised CK	4400	yes	n.a.	+	-	able	able	LL (AS)	-	+	

N.39	59	m	38	left LL weakness	3000	yes	-	+/-		unable	unable	thighs (AS)	-	+	hypertension, KH (AS)
N.40A	32	m	21	decreased endurance, inability standing on right tiptoes and raised CK	4200-22.000	yes	-	++	+	unable	able	adductors, quadriceps and calves	-	+	KH
N.40B	13	m	-	-	1970	yes	-	-	-	able	able	-	-	-	
N.40C	23	f	21	myalgia	861	yes	-	-	-	able	able	-	-	-	
N.41	56	m	35	difficulties running	1168-3612	yes	-	++	++	unable	able	thighs and calves	-	-	
N.42	44	m	39	distal weakness and calf wasting	2666- 4200	yes	-	+	++	unable	able	UL (distally), thighs, calves	-	-	hand weakness, back twitching

Legend: Pt, patient number; CK, creatine kinase; UL, upper limbs; LL, lower limbs; AS, asymmetry; m, male patient; f, female patient; diff, able with difficulties; n.a, data not available; TA, Achilles tendons; KH, knee hyperextension; IHD, ischaemic heart disease; FVC, forced vital capacity; CTS: carpal tunnel syndrome; +, ++, +++: grade of weakness (from milder to more severe)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Table S1. Patients with ANO5 gene mutations

Patient	allele 1	allele 2	Geographic origin
Patients with exonic and intronic changes with uncertain pathogenicity			
N.57-N.58	c.155A>G	-	Great Britain (2)
N.59	c.746C>G	-	Great Britain
N.60	c.968C>G	-	Pakistan
N.61	c.2256G>A	-	Great Britain
N.62	c.2387C>T	-	Great Britain
N.63	c.2698A>C.	-	Germany
N.64-67	c.364-8dupT	c.364-8dupT	Africa (2) and Great Britain (2)
N.68	c.1119+35G>A	c.1181-48T>A	Germany
N.69	c.139-59dupT	-	n.a.
N.70-78	c.364-8dupT	-	Africa (1) and Great Britain (8)

Legend: ANO5 gene, Gene Bank accession number NM_213599.2. Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the ATG translation initiation codon in the reference sequence, according to journal guidelines (www.hgvs.org/mutnomen). The initiation codon is codon 1.

Review